drugset / Trial / NCT02157324
Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is evaluating the safety and efficacy of the combined use of acalabrutinib and ACP-319, for the treatment of chronic lymphocytic leukemia (CLL)
Timeline
- Start
- 2014-08-18
- Primary completion
- 2020-07-20
- Completion
- 2026-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ACP-319 | Unknown | — | — |
| Subject | Acalabrutinib | Small molecule | — | — |